Asv Pharmatech Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 08-11-2024
- Paid Up Capital ₹ 1.00 Cr
as on 08-11-2024
- Company Age 3 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.50 Cr
as on 08-11-2024
- Revenue 67.39%
(FY 2023)
- Profit 61.27%
(FY 2023)
- Ebitda -118.39%
(FY 2023)
- Net Worth 131.24%
(FY 2023)
- Total Assets 47.61%
(FY 2023)
About Asv Pharmatech
The Corporate was formerly known as Asv Sales Corporation Private Limited. The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹3.50 Cr.
Vinayak Bhagwat, Sulakshana Bhagwat, and Sumit Aher serve as directors at the Company.
- CIN/LLPIN
U33209MH2021PTC358831
- Company No.
358831
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Apr 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Asv Pharmatech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinayak Bhagwat  | Director | 13-Apr-2021 | Current |
| Sulakshana Bhagwat | Director | 13-Apr-2021 | Current |
| Sumit Aher | Director | 13-Apr-2021 | Current |
Financial Performance of Asv Pharmatech.
Asv Pharmatech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 67.39% increase. The company also saw a substantial improvement in profitability, with a 61.27% increase in profit. The company's net worth Soared by an impressive increase of 131.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Asv Pharmatech?
Unlock access to Asv Pharmatech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 21 Mar 2024 | ₹3.15 Cr | Open |
Others Creation Date: 08 Sep 2022 | ₹3.50 M | Open |
How Many Employees Work at Asv Pharmatech?
Asv Pharmatech has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Asv Pharmatech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Asv Pharmatech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
